Research

      Investigator Initiated Studies (IIS) Program

      As part of our vision of a smoke-free future, Philip Morris International (PMI) recognizes that independent research is critical to a thorough assessment of the risk-reduction potential of smoke-free products. This is why we support investigator initiated studies on our products, conducted by qualified third-party investigators. 

      How to apply

      We invite interested investigators to submit a study concept proposal to the IIS program. You can find here the guidelines and the terms and conditions of the program.

      Steps for application:

      1. Please fill out the short IIS concept proposal submission template.
      2. Submit your proposal in this template, and any questions about the submission process, via email to iis.pmi@pmi.com.

       

      Topics of interest

      The scope of the IIS program includes aerosol chemistry, toxicology, systems biology, pre-clinical, and clinical studies. You can find the list of studies supported under the IIS program, both past and present. You can also find a list of IIS program publications.

      IIS Program

      Learn more about the IIS program

      You can check out the list of supported Investigator Initiated Studies and find the publications that have resulted from this program.

      Multiple transparent test tubes in laboratory.
      Related Articles

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.